ATLANTA, GA (Globe Newswire – January 14, 2026) — Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) complied with federal securities laws. On December 31, 2025, Corcept disclosed that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Following this news, the price of the Company’s stock dropped.

If you purchased Corcept stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/corcept-therapeutics/ to discuss your legal rights.